Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 19/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 15/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 8/20 | 1.00 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4936485 | 1.00 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL4942578 | 1.00 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL4936796 | 1.00 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL4936479 | 1.00 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL4942572 | 1.00 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL4942662 | 1.00 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL2447747 | 1.00 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL2447750 | 1.00 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL4941082 | 1.00 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL4942653 | 1.00 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113388-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | claimed |
| US-20090042885-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-12 | — | — | US | claimed |
| EP-1409455-B1 | PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2006-01-04 | — | — | EP | claimed |
| US-20050124577-A1 | 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | claimed |
| US-6900336-B2 | 8-aza-11-deoxy prostaglandin analogues | SYNTEX (U.S.A.) LLC (US) | 2005-05-31 | — | — | US | claimed |
| EP-1481976-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | claimed |
| US-20030120079-A1 | Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction | SYNTEX (U.S.A.) LLC | 2003-06-26 | — | — | US | claimed |
| US-8026273-B2 | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| US-7858610-B2 | Preventive and/or remedy for lower urinary tract diseases containing EP4 agonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20100113388-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-7683094-B2 | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-03-23 | — | — | US | disclosed |
| US-20090042885-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-7402605-B2 | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
| US-20080021021-A1 | Preventive And/Or Remedy For Lower Urinary Tract Diseases Containing Ep4 Agonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-1782830-A1 | PREVENTIVE AND/OR REMEDY FOR LOWER URINARY TRACT DISEASES CONTAINING EP4 AGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-09 | — | — | EP | disclosed |
| EP-1409455-B1 | PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2006-01-04 | — | — | EP | disclosed |
| US-20050124577-A1 | 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
| US-6900336-B2 | 8-aza-11-deoxy prostaglandin analogues | SYNTEX (U.S.A.) LLC (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1481976-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20030120079-A1 | Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction | SYNTEX (U.S.A.) LLC | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124577-A1 | 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | PTGER2, PTGIS, HPGDS | PTGER4 16/4885PTGER2 1/4885PTGER3 12/4885 |
| US-20090042885-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | PTGER2, PTGIS, HPGDS | PTGER4 19/4885PTGER2 1/4885PTGER3 16/4885 |
| US-20080021021-A1 | Preventive And/Or Remedy For Lower Urinary Tract Diseases Containing Ep4 Agonist | PTGER4, PTGES3, CYSLTR1 | PTGER4 1/4885PTGER2 13/4885PTGER3 4/4885 |
| US-20030120079-A1 | Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction | PTGER4, FFAR4, PTGER1 | PTGER4 1/4885PTGER2 15/4885PTGER3 11/4885 |
| US-20100113388-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | PTGER2, PTGIS, HPGDS | PTGER4 19/4885PTGER2 1/4885PTGER3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.